This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Medtronic Stock a Buy Pre-Q4 Earnings? Key Metrics to Watch
by Urmimala Biswas
Despite challenges, Medtronic demonstrates the resilience of its underlying business fundamentals, delivering consistent mid-single-digit organic revenue growth.
Abbott Outpaces Peers Defying Tariff Woes: Is ABT Stock a Smart Buy?
by Urmimala Biswas
Despite trade policy challenges, Abbott's global footprint and 90 manufacturing sites offer flexibility to manage regional risks and reroute supply chains.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific
by Zacks Equity Research
GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific are part of the Zacks top Analyst Blog.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know
by Urmimala Biswas
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
PBH or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. ABT: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic
by Zacks Equity Research
Abbott Laboratories, Boston Scientific and Medtronic are included in this Analyst Blog.
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
by Urmimala Biswas
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction
by Zacks Equity Research
Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction are part of the Zacks top Analyst Blog.
Top Analyst Reports for Coca-Cola, Abbott & RTX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Co. (KO), Abbott Laboratories (ABT) and RTX Corp. (RTX), as well as two micro-cap stocks Investors Title Co. (ITIC) and Armanino Foods of Distinction, Inc. (AMNF).
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Buy Boston Scientific Stock Ahead of Q1 Earnings?
by Urmimala Biswas
Banking on robust above-market growth across all business units, BSX is expected to have witnessed strong international momentum in the first quarter.
Company News for Apr 17, 2025
by Zacks Equity Research
Companies In The News Article Are:AMD,ABT, PGR, TRV
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Abbott Q1 Earnings Beat, Sales Miss, Stock Falls in Pre-Market
by Zacks Equity Research
ABT delivers a strong underlying base business performance for the first quarter of 2025.
Pre-Markets Open in The Red
by Zacks Equity Research
Pre-Markets Open in The Red
Retail Sales, Q1 Earnings Show Signs of "Pull Forward"
by Mark Vickery
A trade tariff casualty - NVIDIA - is sending the Nasdaq lower than the other major indexes ahead of the open.
Compared to Estimates, Abbott (ABT) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (ABT) Q1 Earnings Beat Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 1.87% and 0.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it
by Debanjana Dey
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
Robust Specialty Diagnostics Segment Likely to Aid TMO's Q1 Earnings
by Zacks Equity Research
Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's first-quarter 2025 performance.
Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings
by Zacks Equity Research
DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.
Badger Meter Gears Up to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
BMI's performance is likely to have benefited from demand for its solutions. However, the uncertain macro backdrop, higher costs and competition are concerns.